Cubist Sivextro sales to benefit from lack of warnings, says JMP Securities After the FDA approved Cubist's Sivextro treatment for skin infections, JMP Securities notes that the FDA did not require warnings about a number of potential serious side effects to be placed on the drug's label. The firm thinks the absence of these warnings should boost sales of the drug. It reiterates an Outperform rating on Cubist.
News For CBST From The Last 14 Days
Check below for free stories on CBST the last two weeks.
Cubist may receive takeover interest, Bloomberg reports Cubist Pharmaceuticals' (CBST) focus on bacterial infections could attract takeover interest, Bloomberg reports in its Real M&A column. Reference Link